Amy Sullivan

Ms. Sullivan joined Alladapt as Senior Vice President of Clinical Operations in 2018, and her role was expanded to oversee Development Operations in 2019. She has held leadership positions at companies including BioMarin Pharmaceuticals, Roche and Genentech, and spent several years as Director of Clinical Research for a large HIV practice in San Francisco. Prior to joining Alladapt, Ms. Sullivan’s biotech career included increasingly responsible roles at Roche Genentech that involved end-to-end management of early through post-commercial stage clinical trials. Most recently, she was a Clinical Program Group Leader across the Immunology, Ophthalmology and Neuroscience portfolio with Genentech's Research and Early Development (gRED) unit. Prior to her time at Roche Genentech, she was at BioMarin Pharmaceuticals where she contributed to the BLA filing for BioMarin's first marketed product, Aldurazyme for mucopolysaccharidosis type 1.

Ms. Sullivan received a BA in Biological Sciences from the University of California, Santa Barbara.